Gabriel LÃ¡zaro-MuÃ±oz

List of Publications by Year
in descending order

69	974	471509 17	526287 27
papers	citations	h-index	g-index

78	78	78	1254
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Psychosocial Factors Considered When Deciding Whether to Offer Deep Brain Stimulation for Childhood Dystonia. Neuromodulation, 2023, 26, 1646-1652.	0.8	2
2	Researcher Views on Changes in Personality, Mood, and Behavior in Next-Generation Deep Brain Stimulation. AJOB Neuroscience, 2023, 14, 287-299.	1.1	13
3	Capacities and Limitations of Using Polygenic Risk Scores for Reproductive Decision Making. American Journal of Bioethics, 2022, 22, 42-45.	0.9	2
4	Research Comparing iPSC-Derived Neural Organoids to Ex Vivo Brain Tissue of Postmortem Donors: Identity After Life?. AJOB Neuroscience, 2022, 13, 111-113.	1.1	2
5	Trust in Neuroethics. AJOB Neuroscience, 2022, 13, 33-35.	1.1	1
6	Commercialization, Consent, and the Neural Device Industry. AJOB Neuroscience, 2022, 13, 65-67.	1.1	0
7	Researchersâ€™ Ethical Concerns About Using Adaptive Deep Brain Stimulation for Enhancement. Frontiers in Human Neuroscience, 2022, 16, 813922.	2.0	10
8	DBS and Autonomy: Clarifying the Role of Theoretical Neuroethics. Neuroethics, 2021, 14, 83-93.	2.8	17
9	Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?. Molecular Psychiatry, 2021, 26, 60-65.	7.9	54
10	Return of results in a global survey of psychiatric genetics researchers: practices, attitudes, and knowledge. Genetics in Medicine, 2021, 23, 298-305.	2.4	7
11	Perceptions of best practices for return of results in an international survey of psychiatric genetics researchers. European Journal of Human Genetics, 2021, 29, 231-240.	2.8	4
12	Screening embryos for polygenic conditions and traits: ethical considerations for an emerging technology. Genetics in Medicine, 2021, 23, 432-434.	2.4	36
13	Neural Safeguards against Global Impacts of Memory Modification on Identity: Ethical and Practical Considerations. AJOB Neuroscience, 2021, 12, 45-48.	1.1	5
14	Perceptions of Deep Brain Stimulation for Adolescents with Obsessive-Compulsive Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 109-117.	1.3	3
15	Operationalizing Agency in Brain Computer Interface (BCI) Research. AJOB Neuroscience, 2021, 12, 203-205.	1.1	1
16	Child and Adolescent Psychiatristsâ€™ Perceptions of Utility and Self-rated Knowledge of Genetic Testing Predict Usage for Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 657-660.	0.5	16
17	Treatment Search Fatigue and Informed Consent. AJOB Neuroscience, 2021, 12, 77-79.	1.1	4
18	Pressing ethical issues in considering pediatric deep brain stimulation for obsessive-compulsive disorder. Brain Stimulation, 2021, 14, 1566-1572.	1.6	12

#	Article	IF	Citations
19	Testimonial injustice: considering caregivers in paediatric behavioural healthcare. Journal of Medical Ethics, 2021, 47, 738-739.	1.8	2
20	Patient, Caregiver, and Decliner Perspectives on Whether to Enroll in Adaptive Deep Brain Stimulation Research. Frontiers in Neuroscience, 2021, 15, 734182.	2.8	4
21	Psychiatric genomics researchersâ€™ perspectives on best practices for returning results to individual participants. Genetics in Medicine, 2020, 22, 345-352.	2.4	9
22	Parental Attitudes Toward Deep Brain Stimulation in Adolescents with Treatment-Resistant Conditions. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 97-103.	1.3	8
23	Treatment-resistant psychotic symptoms and early-onset dementia: A case report of the 3q29 deletion syndrome. Schizophrenia Research, 2020, 224, 195-197.	2.0	8
24	Strategies to mitigate impacts of the COVID-19 pandemic on patients treated with deep brain stimulation. Brain Stimulation, 2020, 13, 1642-1643.	1.6	5
25	The Ethics of Getting Ahead When All Heads Are Enhanced. AJOB Neuroscience, 2020, 11, 256-258.	1.1	0
26	Researcher Perspectives on Ethical Considerations in Adaptive Deep Brain Stimulation Trials. Frontiers in Human Neuroscience, 2020, 14, 578695.	2.0	21
27	Reconceptualizing Triage to Incorporate Principles of Risk and Uncertainty: An Example from Deep Brain Stimulation Patients with Treatment-Resistant Disorders. American Journal of Bioethics, 2020, 20, 207-209.	0.9	0
28	Pediatric Deep Brain Stimulation for Dystonia: Current State and Ethical Considerations. Cambridge Quarterly of Healthcare Ethics, 2020, 29, 557-573.	0.8	13
29	Is Real-Time ELSI Realistic?. AJOB Empirical Bioethics, 2020, 11, 134-144.	1.6	6
30	Implications of secondary findings for clinical contexts. , 2020, , 155-201.		2
31	Treatment-resistant psychotic symptoms and the 15q11.2 BP1â€“BP2 (Burnside-Butler) deletion syndrome: case report and review of the literature. Translational Psychiatry, 2020, 10, 42.	4.8	11
32	Researcher Perspectives on Data Sharing in Deep Brain Stimulation. Frontiers in Human Neuroscience, 2020, 14, 578687.	2.0	11
33	Ethical, Legal, and Social Implications. , 2020, , 431-442.		2
34	Could Genetic Enhancement Really Lead to Obsolescence?. American Journal of Bioethics, 2019, 19, 34-36.	0.9	2
35	Neuroethics at 15: Keep the Kant but Add More Bacon. AJOB Neuroscience, 2019, 10, 97-100.	1.1	7
36	The need for attention to the ethical, legal, and social implications of advances in psychiatric genomics. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 521-522.	1.7	2

#	Article	IF	Citations
37	Ethical Analysis of â€œMind Readingâ€•or â€œNeurotechnological Thought Apprehensionâ€• Keeping Potential Limitations in Mind. AJOB Neuroscience, 2019, 10, 32-34.	1.1	3
38	Device Removal Following Brain Implant Research. Neuron, 2019, 103, 759-761.	8.1	20
39	GENOME EDITING IN THE CONTEXT OF MENTAL HEALTH DISORDERS. European Neuropsychopharmacology, 2019, 29, S1050.	0.7	0
40	Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians. Harvard Review of Psychiatry, 2019, 27, 53-64.	2.1	19
41	International Society of Psychiatric Genetics Ethics Committee: Issues facing us. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 543-554.	1.7	16
42	THE GENOMICS OF HIGHLY TREATMENT RESISTANT SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S1006-S1007.	0.7	0
43	Ethical and Social Considerations for Increasing Use of DTC Neurotechnologies. AJOB Neuroscience, 2019, 10, 183-185.	1.1	2
44	Psychiatric genetics researchers' views on offering return of results to individual participants. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 589-600.	1.7	17
45	Preventing discrimination based on psychiatric risk biomarkers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 159-171.	1.7	10
46	LEGAL AND ETHICAL IMPLICATIONS OF CRISPR APPLICATIONS IN PSYCHIATRY. North Carolina Law Review, 2019, 97, 1359-1398.	1.0	3
47	Continued access to investigational brain implants. Nature Reviews Neuroscience, 2018, 19, 317-318.	10.2	38
48	Enhance Diversity Among Researchers to Promote Participant Trust in Precision Medicine Research. American Journal of Bioethics, 2018, 18, 44-46.	0.9	17
49	Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntingtonâ€™s Disease. American Journal of Psychiatry, 2018, 175, 400-407.	7.2	9
50	Alienation, Quality of Life, and DBS for Depression. AJOB Neuroscience, 2018, 9, 223-225.	1.1	2
51	Neuroethics of neuromodulation: An update. Current Opinion in Biomedical Engineering, 2018, 8, 45-50.	3.4	22
52	Which Results to Return: Subjective Judgments in Selecting Medically Actionable Genes. Genetic Testing and Molecular Biomarkers, 2017, 21, 184-194.	0.7	17
53	Responsible Translation of Psychiatric Genetics and Other Neuroscience Developments: In Need of Empirical Bioethics Research. American Journal of Bioethics, 2017, 17, 33-35.	0.9	3
54	Genomic Contraindications for Heart Transplantation. Pediatrics, 2017, 139, .	2.1	12

#	Article	IF	Citations
55	Should We Be Concerned About Preserving Agency and Personal Identity in Patients With Adaptive Deep Brain Stimulation Systems?. AJOB Neuroscience, 2017, 8, 73-75.	1.1	11
56	Manipulating Human Memory Through Reconsolidation: Stones Left Unturned. AJOB Neuroscience, 2016, 7, 244-247.	1.1	6
57	Response to Open Peer Commentaries on â€œLooking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choiceâ€• American Journal of Bioethics, 2015, 15, W6-W9.	0.9	0
58	Scientific Social Responsibility: Lessons From the Corporate Social Responsibility Movement. American Journal of Bioethics, 2015, 15, 64-66.	0.9	6
59	Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice. American Journal of Bioethics, 2015, 15, 3-14.	0.9	30
60	Automatic Placement of Genomic Research Results in Medical Records: Do Researchers Have a Duty? Should Participants Have a Choice?. Journal of Law, Medicine and Ethics, 2015, 43, 827-842.	0.9	11
61	CHALLENGES FOR IMPLEMENTING A PTSD PREVENTIVE GENOMIC SEQUENCING PROGRAM IN THE U.S. MILITARY. Case Western Reserve Journal of International Law, 2015, 47, 87-113.	0.0	1
62	Lesions of lateral or central amygdala abolish aversive Pavlovian-to-instrumental transfer in rats. Frontiers in Behavioral Neuroscience, 2014, 8, 161.	2.0	20
63	The Fiduciary Relationship Model for Managing Clinical Genomic â€œIncidentalâ€•Findings. Journal of Law, Medicine and Ethics, 2014, 42, 576-589.	0.9	11
64	MYRIAD AFTER THE PROPRIETARY DATA DILEMMA. North Carolina Journal of Law & Technology, 2014, 15, 597-637.	2.0	17
65	Active vs. reactive threat responding is associated with differential c-Fos expression in specific regions of amygdala and prefrontal cortex. Learning and Memory, 2013, 20, 446-452.	1.3	71
66	Development of an aversive Pavlovian-to-instrumental transfer task in rat. Frontiers in Behavioral Neuroscience, 2013, 7, 176.	2.0	24
67	Endogenous GluR1â€containing AMPA receptors translocate to asymmetric synapses in the lateral amygdala during the early phase of fear memory formation: An electron microscopic immunocytochemical study. Journal of Comparative Neurology, 2010, 518, 4723-4739.	1.6	35
68	Sidman Instrumental Avoidance Initially Depends on Lateral and Basal Amygdala and Is Constrained by Central Amygdala-Mediated Pavlovian Processes. Biological Psychiatry, 2010, 67, 1120-1127.	1.3	121
69	Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats.. Behavioral Neuroscience, 2006, 120, 1093-1102.	1.2	25